| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
113,340,000 |
| Market
Cap: |
108.83(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6758 - $2.34 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Karyopharm Therapeutics is a pharmaceutical company focused on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Co.'s main asset, XPOVIO® (selinexor), a Selective Inhibitors of Nuclear Export compound, is indicated for use in adult patients with multiple myeloma who have received at least one prior therapy; adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
41,140 |
41,140 |
| Total Buy Value |
$0 |
$0 |
$49,985 |
$49,985 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
924,350 |
1,173,939 |
1,216,699 |
1,560,865 |
| Total Sell Value |
$901,474 |
$1,198,663 |
$1,255,793 |
$3,019,031 |
| Total People Sold |
4 |
7 |
7 |
8 |
| Total Sell Transactions |
8 |
26 |
36 |
61 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Poulton Stuart |
EVP, Chief Development Officer |
• – – |
2023-07-28 |
4 |
S |
$1.70 |
$4,837 |
D/D |
(2,845) |
156,286 |
|
55% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2023-07-05 |
4 |
S |
$1.72 |
$6,085 |
D/D |
(3,538) |
805,740 |
|
58% |
|
| Cheng Sohanya Roshan |
EVP & Chief Commercial Officer |
• – – |
2023-06-08 |
4 |
S |
$2.35 |
$4,322 |
D/D |
(1,839) |
211,501 |
|
50% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2023-06-05 |
4 |
S |
$2.24 |
$7,922 |
D/D |
(3,536) |
809,278 |
|
46% |
|
| Mason Michael |
EVP, CFO & Treasurer |
• – – |
2023-06-02 |
4 |
S |
$2.22 |
$1,401 |
D/D |
(631) |
244,730 |
|
44% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2023-05-04 |
4 |
S |
$3.35 |
$12,753 |
D/D |
(3,805) |
812,814 |
|
54% |
|
| Rangwala Reshma |
EVP & Chief Medical Officer |
• – – |
2023-04-20 |
4 |
S |
$4.03 |
$27,416 |
D/D |
(6,770) |
158,230 |
|
64% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2023-04-04 |
4 |
S |
$3.97 |
$13,883 |
D/D |
(3,497) |
816,619 |
|
56% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2023-03-06 |
4 |
S |
$3.16 |
$11,079 |
D/D |
(3,506) |
820,116 |
|
51% |
|
| Cheng Sohanya Roshan |
EVP & Chief Commercial Officer |
• – – |
2023-03-01 |
4 |
S |
$3.03 |
$34,045 |
D/D |
(11,239) |
210,687 |
|
46% |
|
| Mano Michael |
SVP, General Counsel&Secretary |
• – – |
2023-03-01 |
4 |
S |
$3.03 |
$20,835 |
D/D |
(6,878) |
146,122 |
|
46% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2023-03-01 |
4 |
S |
$3.03 |
$100,064 |
D/D |
(33,033) |
823,622 |
|
46% |
|
| Mitchener Stephen |
SVP, Chief Business Officer |
• – – |
2023-03-01 |
4 |
S |
$3.03 |
$19,257 |
D/D |
(6,357) |
128,313 |
|
46% |
|
| Mason Michael |
EVP, CFO & Treasurer |
• – – |
2023-03-01 |
4 |
S |
$3.03 |
$33,942 |
D/D |
(11,205) |
245,361 |
|
46% |
|
| Rangwala Reshma |
EVP & Chief Medical Officer |
• – – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
165,000 |
|
- |
|
| Cheng Sohanya Roshan |
EVP & Chief Commercial Officer |
• – – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
221,926 |
|
- |
|
| Mano Michael |
SVP, General Counsel&Secretary |
• – – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
70,000 |
153,000 |
|
- |
|
| Paulson Richard A. |
President and CEO |
• • – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
252,000 |
856,655 |
|
- |
|
| Poulton Stuart |
EVP, Chief Development Officer |
• – – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
95,000 |
159,131 |
|
- |
|
| Mitchener Stephen |
SVP, Chief Business Officer |
• – – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
134,670 |
|
- |
|
| Mason Michael |
EVP, CFO & Treasurer |
• – – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
95,000 |
256,566 |
|
- |
|
| Mason Michael |
EVP, CFO & Treasurer |
• – – |
2023-02-27 |
4 |
S |
$3.04 |
$8,509 |
D/D |
(2,802) |
161,566 |
|
48% |
|
| Poulton Stuart |
EVP, Chief Development Officer |
• – – |
2023-02-15 |
4 |
S |
$3.16 |
$18,717 |
D/D |
(5,869) |
64,131 |
|
49% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2023-02-06 |
4 |
S |
$3.40 |
$13,430 |
D/D |
(3,950) |
604,655 |
|
39% |
|
| Mason Michael |
EVP, CFO & Treasurer |
• – – |
2023-02-06 |
4 |
S |
$3.40 |
$14,079 |
D/D |
(4,141) |
164,368 |
|
39% |
|
620 Records found
|
|
Page 3 of 25 |
|
|
0.01 (1.31%) 
